The SPHS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SPHS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The SPHS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View SPHS Detailed Price Forecast - CNN Money||View SPHS Detailed Summary - Google Finance|
|View SPHS Detailed Summary - Yahoo! Finance||View SPHS Stock Research & Analysis - Zacks.com|
|View SPHS Trends & Analysis - Trade-Ideas||View SPHS Major Holders - Barrons|
|View SPHS Call Transcripts - NASDAQ||View SPHS Breaking News & Analysis - Seeking Alpha|
|View SPHS Annual Report - CompanySpotlight.com||View SPHS OTC Short Report - OTCShortReport.com|
|View SPHS Fundamentals - TradeKing||View SPHS SEC Filings - Bar Chart|
|View Historical Prices for SPHS - The WSJ||View Performance/Total Return for SPHS - Morningstar|
|View the Analyst Estimates for SPHS - MarketWatch||View the Earnings History for SPHS - CNBC|
|View the SPHS Earnings - StockMarketWatch||View SPHS Buy or Sell Recommendations - MacroAxis|
|View the SPHS Bullish Patterns - American Bulls||View SPHS Short Pain Metrics - ShortPainBot.com|
|View SPHS Stock Mentions - StockTwits||View SPHS Stock Mentions - PennyStockTweets|
|View SPHS Stock Mentions - Twitter||View SPHS Investment Forum News - Investor Hub|
|View SPHS Stock Mentions - Yahoo! Message Board||View SPHS Stock Mentions - Seeking Alpha|
|View Insider Transactions for SPHS - SECform4.com||View Insider Transactions for SPHS - Insider Cow|
|View SPHS Major Holdings Summary - CNBC||View Insider Disclosure for SPHS - OTC Markets|
|View Insider Transactions for SPHS - Yahoo! Finance||View Institutional Holdings for SPHS - NASDAQ|
|View SPHS Stock Insight & Charts - FinViz.com||View SPHS Investment Charts - StockCharts.com|
|View SPHS Stock Overview & Charts - BarChart||View SPHS User Generated Charts - Trading View|
Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
Posted on Wednesday March 13, 2019
SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the fourth quarter and full year 2018 and recent corporate highlights. "During the past year, Sophiris has made important progress in determining the ideal method for topsalysin administration as a focal treatment for localized prostate cancer," said Randall E. Woods, president and CEO of Sophiris. "The Phase 2b study provided a compelling look at this potential, showing that a single administration of topsalysin led to a clinical response in 27% of patients, including a complete ablation of tumor in 16% of patients.
SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer…
Posted on Wednesday December 19, 2018
A total of 38 patients received a single administration of topsalysin to treat a clinically significant tumor, which was defined for this study as either a Gleason score of 6 (pattern 3 + 3) and greater than or equal to 6 mm maximum cancer core length (MMCL), or a Gleason score of 7 (pattern 3 + 4) and less than or equal to 10 mm MCCL. Ten patients received a second administration of topsalysin due to having a partial response to the first treatment, however their lesions were still clinically significant.
Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
Posted on Monday December 17, 2018
SAN DIEGO and VANCOUVER, British Columbia, Dec. 17, 2018 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today provides an update from its Phase 2b study of topsalysin for localized prostate cancer, including top-line safety and biopsy results from the patients who received a second administration of study drug, which appeared to be safe and generally well-tolerated. Additional benefit was not observed on targeted biopsy six months after re-treatment with a second administration of topsalysin. As previously stated, a total of 27% of patients (10/37) demonstrated a clinical response six months following a single administration of topsalysin.
Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?
Posted on Thursday December 06, 2018
If you own shares in Sophiris Bio Inc (FRA:BFF1) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...